In its Final Appraisal Report, the All Wales Medicines Strategy Group (AWMSG) supported the use of  Fentanyl (Instanyl™) as an option for use within NHS Wales for the treatment for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.

Fentanyl intranasal spray should only be considered as an option for the management of breakthrough cancer pain when immediate release oral opioids (e.g. morphine, oxycodone) are either inadequate or unsuitable.

Fentanyl intranasal spray may be suitable for shared care but should be initiated by, and remain under the supervision of, a physician experienced in the management of opioid therapy in cancer patients.